# KLOW Peptide Dosage — Component Research Doses and Pharmacokinetics > KLOW peptide dosage context from the component literature: composition of the typical 80 mg research vial, component-level study doses, half-life data, and the pharmacokinetic mismatch. The canonical 80 mg vial composition, component-level research doses by species and route, a half-life ledger across the four arms, and the pharmacokinetic mismatch that is structural to the blend. ## In plain English KLOW peptide dosage is a complicated subject because no validated human dose exists for the blend — and cannot exist until a controlled human study is conducted. The KLOW peptide dosage context on this page is limited to what the component research measured, organized by ingredient. The typical research vial contains 80 mg total — mostly GHK-Cu, with smaller equal shares of BPC-157, TB-500 and KPV. Each component was studied at different doses in different species; those numbers cannot simply be added together or rescaled into a single 'KLOW dose'. The pharmacokinetics (how fast each compound enters and leaves the body) are markedly different across the four components, creating a structural mismatch: a single vial cannot hold all four at matched exposures at the same time. ## KLOW peptide dosage The most widely cited KLOW research-vial composition is 80 mg total — GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg, reconstituted with bacteriostatic water for laboratory handling. GHK-Cu is the mass-dominant component at approximately 62.5% of the total by mass. No validated human dosing exists for the blend. Component-level research doses differ widely by species and route and are not additive into a single 'KLOW dose'. Every dosing context below is research-only — it describes what was administered to which species at which dose in a published study, not a human use recommendation. ## klow dosage **BPC-157 research doses.** In rodent tissue-repair studies, BPC-157 has been administered intraperitoneally at 10 microg, 10 ng or 10 pg per rat (daily injections) [2]. In the 2025 human IV safety pilot, doses of 10 mg on day 1 and 20 mg on day 2 in 250 cc saline over a 1-hour infusion were administered to two healthy adults; this was a safety pilot, not an efficacy protocol [6]. **GHK-Cu research doses.** In vitro effects on gene expression and collagen synthesis have been measured at 1–10 nM [5]. Topical GHK-Cu in clinical skin studies has been used in formulated cosmetic concentrations; the 2017 angiogenesis study used topical liposomal GHK-Cu in a mouse scald-wound model [10]. The clinical skin-regeneration review (2015) documents effects across topical formulations [4]. **KPV research doses.** In vitro NF-kappaB suppression and cytokine reduction occurred at nanomolar concentrations in human intestinal epithelial and immune cell lines [3]. In DSS/TNBS mouse colitis models, KPV was administered orally at 100 microM in drinking water [3]. **TB-500 / thymosin beta-4 research doses.** In the 1999 rat wound model, full-length thymosin beta-4 was used topically and intraperitoneally at dose ranges from approximately 10 pg (effective for keratinocyte migration in vitro) to standard rodent IP doses in vivo [1]. The TB-500 heptapeptide fragment has its own published dose-response data distinct from the full-length protein; users should not equate the two. ## KLOW peptide dosage and frequency Because no validated human KLOW peptide dosage and frequency protocol exists, frequency of administration cannot be specified from the scientific literature. Component studies used a range of protocols: once-daily intraperitoneal injections for BPC-157 in rat tendon models [2], topical applications in wound models [1,10], oral administration for KPV in colitis models [3]. Reconstituted peptide solutions are typically refrigerated; stability of the co-dissolved blend at room temperature or during extended storage has not been formally characterized for this mixture. Copper(II) in GHK-Cu can participate in redox chemistry with co-dissolved peptides — an additional stability and compatibility consideration unique to the KLOW co-formulation. The component half-life mismatch is the central pharmacokinetic fact for the blend: BPC-157 has a short rodent elimination half-life (under approximately 30 minutes in formal PK data); the tripeptides KPV and GHK-Cu clear faster still; and the TB-500 fragment's pharmacokinetics are not well characterized relative to native thymosin beta-4. No single dosing frequency can keep all four components at matched exposures simultaneously. ## Administration routes in the component literature The component literature spans multiple administration routes. BPC-157 has been studied subcutaneously, intraperitoneally, orally and intra-articularly in rodent models, and intravenously in the 2025 human pilot [6]. GHK-Cu research covers topical routes extensively with cosmetic/wound clinical data, plus in vitro cell-culture application and liposomal delivery in mouse models [10]. KPV was studied orally in mouse colitis models via drinking water and in vitro in cell culture [3]; targeted GI delivery leveraging PepT1 expression is a feature of its mechanism. Thymosin beta-4 / TB-500 research has covered topical, intraperitoneal and systemic routes in rodents; more recent exosome-loaded hydrogel delivery was studied in wound models [14]. None of these routes or dose ranges applies to the KLOW blend as a co-formulation — they describe single-component protocols in well-defined experimental contexts, not human administration guidance. --- A technical schematic of four separate peer-reviewed literatures — each component dimensioned to its own studies, the untested combination held as the honest blank dimension.